Affinity Asset Advisors, LLC Krystal Biotech, Inc. Transaction History

Affinity Asset Advisors, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$108.01 - $179.35 $188,585 - $313,145	1,746 Added 6.98%	26,746 $4.76 Million
Q4 2023 Feb 13, 2024	SELL	$96.0 - $128.29 $3.12 Million - $4.17 Million	-32,500 Reduced 56.52%	25,000 $3.1 Million
Q3 2023 Nov 14, 2023	BUY	$108.51 - $130.22 $6.24 Million - $7.49 Million	57,500 New	57,500 $6.67 Million

311

24.4M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $5.07B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Asset Advisors, LLC with notifications on news.